CELZHealthcare · Biotechnology

CELZ Stock Forecast: Creative Medical Technology Holdings, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$0.66

−3.45% on the day

The 1 Wall Street analysts covering Creative Medical Technology Holdings, Inc. hold a median 12-month price target of $20 — +2953.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$5.0M

Ticker Nerd rank

21/ 100

Median analyst target

$20

Analysts covering

Revenue$0.0

Operating income−$1.6M

Net income−$1.5M

Free cash flow−$1.5M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−11.5%

−29.9%

YTD

−66.6%

−80.0%

From 52W high

−80.0%

From 52W low

+0.1%

$0.65

$3.28

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CELZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Creative Medical Technology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

21/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Revisions

Accruals

Momentum

Issuance

Quality

Volatility

Value

Size (95): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CELZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $20Median $20High $20

The green dot is the last close — the median target sits +2953.4% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
25 Feb 2022	Roth Capital	Initiates	Buy	$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CELZ appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

CELZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Creative Medical Technology Holdings, Inc. returned −80.0% against +12.4% for the S&P 500, dividends included.

CELZ vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

Creative Medical Technology Holdings, Inc. (CELZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 2.8×
Price / sales: 1657.7×
Price / book: 0.5×
EV / EBITDA: 0.7×

Growth & margins

Revenue growth (YoY): −100.0%
Earnings growth (YoY): −100.0%
Gross margin: —
Operating margin: −208004.4%
Net margin: 63.4%

Returns & dividend

Return on equity: −77.9%
Return on assets: −47.3%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Creative Medical Technology Holdings, Inc. (CELZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Creative Medical Technology Holdings, Inc. has a market value of $5.0M and an enterprise value of −$4.5M.
Revenue in the twelve months to 30 June 2026: $3K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$6.0M, a −201285.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$6.0M.
Creative Medical Technology Holdings, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Shares outstanding: 4.7M.
Trailing P/E: 2.8×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Creative Medical Technology Holdings, Inc. employs 4 people — $750.0 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

CELZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
CELZCreative Medical Technology Holdings, Inc.	$5.0M	21
TRAWTraws Pharma, Inc.	$4.5M	48
CRISCuris, Inc.	$4.0M	39
AZTRAzitra, Inc.	$4.7M	42
XBIOXenetic Biosciences, Inc.	$4.8M	31
DRMADermata Therapeutics, Inc.	$3.8M	33
LIMNLiminatus Pharma, Inc.	$3.8M	11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Creative Medical Technology Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CELZ news & analysis

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

GlobeNewsWire · 20 Oct 2026positive

Creative Medical Technology Holdings highlighted findings from a six-month study of its investigational Ultrasome platform in 30 patients with bilateral knee osteoarthritis. Twenty-eight participants (93%) met the study-defined response criteria; the headline also reports a 65% reduction in average pain scores.

Why it matters — The findings provide CELZ watchers an update on clinical results for the company’s investigational regenerative medicine platform.

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

GlobeNewsWire · 17 Sept 2026positive

Creative Medical Technology Holdings, Inc. announced it has filed a new U.S. provisional patent application intended to expand intellectual property protection surrounding Ultrasome, its proprietary cell-free regenerative medicine platform. The filing adds to the company's intellectual property portfolio.

Why it matters — CELZ watchers would care because expanded patent protection for the Ultrasome platform could strengthen the company's competitive position in its regenerative medicine pipeline.

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

GlobeNewsWire · 20 Aug 2026positive

Creative Medical Technology Holdings announced that all patients have been enrolled and treated across its entire FDA-cleared ADAPT clinical trial for CELZ-201/Olastrocel, including the opioid expansion cohort. With enrollment and treatment complete, the company expects reduced clinical execution expenses and will focus on follow-up, data maturation, RMAT evaluation, and Phase 3 planning with the FDA.

Why it matters — Completion of enrollment and treatment across the entire ADAPT trial marks a key clinical milestone for CELZ-201/Olastrocel and signals a transition toward RMAT evaluation and Phase 3 planning that could reduce expenses and extend the company's operating runway.

Creative Medical Technology Stock Surges After Key Patent Win

Benzinga · 6 Aug 2026positive

Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares surged Thursday afternoon following an intellectual property milestone related to a key patent win.

Why it matters — A key patent win represents an intellectual property milestone for CELZ that could affect the company's competitive position.

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

GlobeNewsWire · 6 Aug 2026positive

Creative Medical Technology Holdings, Inc. announced it received a notice of allowance for a new U.S. patent covering exosome-based immunotherapy for type 1 diabetes. The patent protects the cell-free MyeloCelz™ exosome technology, which is designed to suppress autoimmune destruction of insulin-producing cells, and deepens IP protection across the company's MyeloCelz™, CELZ-101 and CELZ-201 diabetes platforms.

Why it matters — A CELZ watcher would care because the newly allowed patent strengthens the company's intellectual property protection across its multi-program diabetes strategy, supporting its cell-free exosome technology.

FAQ

Frequently asked questions about CELZ stock

What is the CELZ stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Creative Medical Technology Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CELZ stock a buy right now?

Of the 1 analysts covering Creative Medical Technology Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Creative Medical Technology Holdings, Inc. 21 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CELZ?

As at 31 Oct 2026, Creative Medical Technology Holdings, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will CELZ stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +2953.4% from the last close, and Ticker Nerd's factor model ranks Creative Medical Technology Holdings, Inc. 21 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CELZ stock forecast for 2030?

No analyst covering Creative Medical Technology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has CELZ stock performed over the past year?

Creative Medical Technology Holdings, Inc. returned -80.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Creative Medical Technology Holdings, Inc. do?

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on regenerative medicine and novel biological therapeutics.

What is the latest news on CELZ?

The most recent item we track (GlobeNewsWire, 20 Oct 2026): "Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study". Creative Medical Technology Holdings highlighted findings from a six-month study of its investigational Ultrasome platform in 30 patients with bilateral knee osteoarthritis. Twenty-eight participants (93%) met the study-defined response criteria; the headline also reports a 65% reduction in average pain scores.

Company

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on regenerative medicine and novel biological therapeutics. The company develops products and programs across immunology, endocrinology, urogynecology, urology, neurology, and orthopedics, with an emphasis on stem cell-based and cell-derived approaches. Its portfolio includes therapies and platforms such as CaverStem, FemCelz, StemSpine, ImmCelz, and AlloStem, which are designed for a range of conditions including sexual health, spinal disorders, immune-related diseases, and other unmet medical needs. Creative Medical Technology Holdings, Inc. serves a specialized role in the healthcare market by advancing regenerative technologies from development into commercial use and clinical evaluation. Headquartered in Phoenix, Arizona, the company concentrates on translating biomedical research into targeted treatment options for patients and clinicians.

CEO Mr. Timothy Warbington · 4 employees · United States · https://www.creativemedicaltechnology.com